{Reference Type}: Journal Article
{Title}: Management of donor-specific antibodies in lung transplantation.
{Author}: Brandon W;Dunn C;Bollineni S;Joerns J;Lawrence A;Mohanka M;Timofte I;Torres F;Kaza V;
{Journal}: Front Transplant
{Volume}: 2
{Issue}: 0
{Year}: 2023
暂无{DOI}: 10.3389/frtra.2023.1248284
{Abstract}: The formation of antibodies against donor human leukocyte antigens poses a challenging problem both for donor selection as well as postoperative graft function in lung transplantation. These donor-specific antibodies limit the pool of potential donor organs and are associated with episodes of antibody-mediated rejection, chronic lung allograft dysfunction, and increased mortality. Optimal management strategies for clearance of DSAs are poorly defined and vary greatly by institution; most of the data supporting any particular strategy is limited to small-scale retrospective cohort studies. A typical approach to antibody depletion may involve the use of high-dose steroids, plasma exchange, intravenous immunoglobulin, and possibly other immunomodulators or small-molecule therapies. This review seeks to define the current understanding of the significance of DSAs in lung transplantation and outline the literature supporting strategies for their management.